Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 10 of 10« First...678910

Opexa Therapeutics Slashes 30% of Workforce in Restructuring Plan

March 3, 2016 By Alex Keown, BioSpace.com Breaking News Staff   THE WOODLANDS, Texas – Opexa Therapeutics (OPXA) is handing out pink slips to about 30 percent of its workforce, including the chief financial officer, as the company undergoes a restructuring plan to extend the company’s cash runaway into the first quarter of 2017, the […]

Read More »

Google says its engineers working with UNICEF to map Zika

Alphabet Inc’s Google said on Thursday that its engineers were working with U.N. child agency UNICEF to analyze data in an effort to map and anticipate the spread of the Zika virus, linked to birth defects among children in Brazil. Google said in a statement it was providing a $1 million grant to the United […]

Read More »

Republican Trump releases healthcare proposals

U.S. Republican presidential front-runner candidate Donald Trump on Wednesday unveiled proposals for reforming U.S. healthcare that included repealing Obamacare, allowing prescription drugs to be imported, and turning the Medicaid program for the poor into block grants to states. The plan also calls for the sale of health insurance plans across state lines, full deduction of […]

Read More »

NY attorney general to investigate insurers over hepatitis C drugs

New York state Attorney General Eric Schneiderman’s office has asked 16 health insurers for documentation on patients who have been denied coverage of drugs used to cure hepatitis C, a person familiar with the matter told Reuters on Wednesday. Schneiderman’s office also requested details on procedures followed by the companies to authorize the drugs used […]

Read More »

Documents Accuse Bayer, Johnson & Johnson of Deceiving The New England Journal of Medicine

NEW YORK — In the ongoing legal concerns surrounding the anticlotting drug Xarelto developed by Janssen Pharmaceuticals, a Johnson & Johnson (JNJ) company, and marketed by Bayer (BAYZF), a new wrinkle surfaced in a legal brief filed last week in federal court in New Orleans claiming the two companies mislead editors at the New England […]

Read More »

Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company – ImmuneOncia

SAN DIEGO and SEOUL, South Korea, March 2, 2016 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Yuhan Corporation (000100.KS; Yuhan), one of the largest and most respected pharmaceutical companies in South Korea, today announced that they have entered into […]

Read More »

First Gene For Grey Hair Found, University College London Study

The first gene identified for greying hair has been discovered by an international UCL-led study, confirming greying has a genetic component and is not just environmental. Published today in Nature Communications, the study analyzed a population of over 6,000 people with varied ancestry across Latin America to identify new genes associated with hair color, greying, […]

Read More »

Cuba reports first case of Zika in Venezuelan doctor

Cuba reported its first case of Zika on Wednesday, diagnosed in a 28-year-old Venezuelan doctor whose husband and brother-in-law previously contracted the virus in their home country.   The World Health Organization declared the Zika outbreak, suspected of causing thousands of birth defects in Brazil, an international health emergency on Feb. 1, although much about […]

Read More »

UK cost agency rejects leukemia drug from J&J and AbbVie

A new leukemia drug viewed by industry experts as a future blockbuster has been rejected by Britain’s healthcare cost-effectiveness agency NICE, which said it could not be confident the medicine represented an effective use of resources. Imbruvica has a list price of 55,954.50 pounds ($78,000) a year, although it is being offered at an undisclosed […]

Read More »

New FDA guidelines aim to prevent Zika transmission via tissue, cell donation

The U.S. Food and Drug Administration on Tuesday issued new recommendations aimed at reducing the risk of Zika virus transmission through donated human tissues and cells used in surgical or reproductive procedures, such as umbilical cord blood, corneas and heart valves. The guidance is part of the agency’s ongoing efforts to protect human cellular, tissue […]

Read More »

U.S. FDA Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey for the Treatment of HIV-1 Infection

– Odefsey is the Smallest Single Tablet HIV Regimen –   FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Emtricitabine and tenofovir alafenamide […]

Read More »

Novo Nordisk and AstraZeneca seek tonic from key drug trials

Novo Nordisk and AstraZeneca, two drugmakers whose financial outlooks disappointed investors last month, are both hoping for a boost in the coming weeks from results of two closely watched clinical trials.   AstraZeneca wants to prove its blood-thinner Brilinta can help stroke patients, in addition to those with heart problems, while Novo aims to showcase the […]

Read More »

Multiple Failed Trials Lead Chimerix to Slash 20% of Workforce

In light of three failed clinical trials and disappointing financial statements, Durham, N.C.-based Chimerix (CMRX) cut about 20 percent of its workforce.   Chimerix focuses on the development of antiviral medications. At its recent fourth-quarter financial statements, the company reported a net loss of $117.4 million, or $2.67 per basic and diluted share for last […]

Read More »

AstraZeneca sells drug for $70 million as divestment drive continues

AstraZeneca has sold rights to a non-core drug to a unit of Kyowa Hakko Kirin for an upfront payment of $70 million, a day after getting $500 million for two ageing heart medicines.   The British-based drugmaker has been divesting peripheral products to help pay the bills as it invests in new medicines, while taking […]

Read More »

Comeback Kid Exelixis Wrangles Cancer Deal Worth $855 Million with Ipsen

March 1, 2016By Mark Terry, BioSpace.com Breaking News Staff   South San Francisco-based Exelixis, Inc. (EXEL) and Paris-based Ipsen (IPN.PA) announced yesterday that they had inked an exclusive licensing agreement to commercialize and develop cabozantinib, Exelixis’ lead cancer drug. Ipsen will gain exclusive rights to commercialize cabozantinib for current and future indications outside the U.S., […]

Read More »

Page 10 of 10« First...678910

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom